Myomo (NYSEAMERICAN:MYO) Posts Earnings Results, Beats Estimates By $0.01 EPS

Myomo (NYSEAMERICAN:MYO) announced its quarterly earnings data on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. The company had revenue of $12.33 million during the quarter, compared to the consensus estimate of $11.51 million. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%.

Here are the key takeaways from Myomo’s conference call:

• Revenue reached a record $12.3 million, up 22% year over year, while gross margin increased to 71.3% from 63.8% and adjusted EBITDA reached approximately break-even.
• Recurring patient sources rose to 54% of revenue from 33% a year ago, and MyoConnect had referrals from more than 500 facilities. The company also reported a record 258 orders and payer agreements or pending agreements covering an additional 35 million lives.
• Myomo narrowed its 2026 revenue outlook to $46 million–$47 million, from the prior $45 million–$47 million range, and expects second-half cash burn below $2 million. Management expects a modest sequential gross-margin increase in Q4, though operating expenses are expected to rise modestly.
• Pipeline additions fell to 600, with management citing summer-season effects, temporary MyoConnect staffing constraints, and inefficient direct-to-patient lead generation. October direct-billing pipeline additions improved about 30% from the Q3 monthly average, but Q4 pipeline activity is typically seasonally lower.
• Net loss was $4.2 million versus $3.7 million a year earlier, despite a narrower operating loss; results included an approximately $1.8 million non-cash derivative-liability valuation charge and interest expense tied to the term loan.

Myomo Price Performance

NYSEAMERICAN MYO opened at $1.40 on Tuesday. Myomo has a 12 month low of $0.60 and a 12 month high of $1.89. The stock has a market cap of $55.45 million, a price-to-earnings ratio of -4.12 and a beta of 1.74. The company’s 50 day moving average is $1.38 and its two-hundred day moving average is $1.09. The company has a current ratio of 2.31, a quick ratio of 2.01 and a debt-to-equity ratio of 1.98.

Insiders Place Their Bets

In other Myomo news, insider Harry Kovelman sold 17,250 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $1.73, for a total value of $29,842.50. Following the completion of the transaction, the insider directly owned 105,983 shares in the company, valued at $183,350.59. This represents a 14.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 47,738 shares of company stock worth $70,662 over the last quarter. 12.14% of the stock is owned by insiders.

Myomo News Roundup

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: Third-quarter revenue rose 22.2% year over year to $12.33 million, topping analyst expectations; gross profit increased 36.4% to $8.8 million. Myomo said it achieved breakeven adjusted EBITDA, reflecting improved operating leverage. Myomo Q3 results
• Positive Sentiment: The company set 2026 revenue guidance at $46 million–$47 million, above the approximately $45.5 million consensus estimate. Management also expects modest sequential gross-margin improvement in Q4. Updated revenue guidance
• Neutral Sentiment: Myomo reported a quarterly loss of $0.07 per share, slightly better than the $0.08 loss analysts expected in earnings summaries, though another report cited a larger diluted loss. Quarterly earnings report
• Negative Sentiment: Despite improved sales and adjusted EBITDA, Myomo remained loss-making; a third-party report cited a $4.2 million net loss and $1.3 million operating cash outflow. The company ended the quarter with $11.1 million in cash, leaving ongoing execution and funding needs as investor risks. Third-party Q3 data

About Myomo

Myomo, Inc is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.

The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.